Federal contract award
70RWMD23C00000017
TS#13 AWARD TO CAPESYM, INC. FOR R&D
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Homeland Security |
| Office | CWMD ACQ DIV |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AJ12 — GENERAL SCIENCE AND TECHNOLOGY R&D SERVICES; GENERAL SCIENCE AND TECHNOLOGY; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $1.4M |
| Current contract value | $1.9M |
| Potential contract value / ceiling | $3.7M |
| Start date | Jul 3, 2023 |
| Current end date | Feb 10, 2027 |
| Potential end date | Feb 10, 2029 |
| Latest award activity | Aug 11, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 11, 2026 | P00005 | $0 | THE PURPOSE OF P00004 IS TO EXERCISE AND FULLY FUND OPTION II/CLIN 2001/ PHASE III LABOR, EXERCISE AND FULLY FUND OPTION II/CLIN 2002/ PHASE III TRAVEL. |
| Feb 10, 2026 | P00004 | $741.2K | THE PURPOSE OF P00004 IS TO EXERCISE AND FULLY FUND OPTION II/CLIN 2001/ PHASE III LABOR, EXERCISE AND FULLY FUND OPTION II/CLIN 2002/ PHASE III TRAVEL. |
| Sep 30, 2025 | P00003 | $0 | THE PURPOSE OF P00003 IS TO EXTEND OPTION END DATE OF OPTION 1/PHASE II/CLIN 1001 AND 1002 FROM 10/3/2025 TO 4/2/2026. |
| Sep 18, 2024 | P00002 | $691.8K | THE PURPOSE OF MOD FOR CONTRACT 70RWMD23C00000017 W/CAPESYM, INC. IS TO DO FULLY FUND OPTION 1/CLN 1001/PH II LABOR IN THE AMOUNT OF $683,689.53. & FUND OPTI 1/CLN 1002/PHA II TRAVEL IN THE AMOUNT OF $8,110.00. |
| Mar 29, 2024 | P00001 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO PROVIDE A PERIOD OF PERFORMANCE EXTENSION FOR CLIN 0001 AND CLIN 0002 WITH A NEW END DATE OF OCTOBER 2, 2024, (FROM APRIL 2, 2024) AT NO ADDITIONAL COST TO THE GOVERNMENT. |
| Jun 27, 2023 | 0 | $0 | TS#13 AWARD TO CAPESYM, INC. FOR R&D |
Estimated positioning window
Feb 10, 2028 – Aug 10, 2028
50/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 50/100. Available recorded signals: 45 points.
- Contract end 2029-02-10 (839 days from calculation)
- +15 points
- 14 historical awards in this buyer and category group
- +15 points
- 6 recorded award transactions
- +10 points
- Latest award action: 2026-08-11
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.